La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
MacroGenics Croissance future
Future contrôle des critères 1/6
Les bénéfices de MacroGenics devraient diminuer de 12.6% par an tandis que son chiffre d'affaires annuel devrait croître de 12.2% par an. Le BPA devrait croître de diminuer de 4.1% par an. Le rendement des capitaux propres devrait être -122.4% dans 3 ans.
Informations clés
-12.6%
Taux de croissance des bénéfices
-4.1%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 30.3% |
Taux de croissance des recettes | 12.2% |
Rendement futur des capitaux propres | -122.4% |
Couverture par les analystes | Good |
Dernière mise à jour | 15 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
Aug 01MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Jul 30We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Jul 12MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
May 13MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
May 13MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Mar 11Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Oct 25MacroGenics: No Near-Term Catalysts
Oct 11Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics
Sep 02MacroGenics Q2 2022 Earnings Preview
Aug 05Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25MacroGenics halts mid-stage head and neck cancer study after fatalities
Jul 11The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
May 09We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials
Feb 25Estimating The Intrinsic Value Of MacroGenics, Inc. (NASDAQ:MGNX)
Feb 18Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 110 | -182 | -222 | -190 | 5 |
12/31/2025 | 95 | -166 | -202 | -69 | 8 |
12/31/2024 | 137 | -136 | -148 | -24 | 9 |
6/30/2024 | 41 | -136 | -157 | -153 | N/A |
3/31/2024 | 43 | -23 | -114 | -111 | N/A |
12/31/2023 | 59 | -9 | -80 | -78 | N/A |
9/30/2023 | 121 | 50 | -22 | -21 | N/A |
6/30/2023 | 152 | 7 | 3 | 5 | N/A |
3/31/2023 | 165 | -91 | -45 | -42 | N/A |
12/31/2022 | 152 | -120 | -91 | -87 | N/A |
9/30/2022 | 93 | -191 | -175 | -171 | N/A |
6/30/2022 | 67 | -219 | -182 | -176 | N/A |
3/31/2022 | 72 | -217 | -179 | -172 | N/A |
12/31/2021 | 77 | -202 | -150 | -144 | N/A |
9/30/2021 | 116 | -146 | -103 | -95 | N/A |
6/30/2021 | 119 | -129 | -113 | -106 | N/A |
3/31/2021 | 108 | -136 | -102 | -97 | N/A |
12/31/2020 | 105 | -130 | -118 | -112 | N/A |
9/30/2020 | 77 | -158 | -148 | -144 | N/A |
6/30/2020 | 78 | -167 | -140 | -136 | N/A |
3/31/2020 | 68 | -152 | -152 | -148 | N/A |
12/31/2019 | 64 | -152 | -139 | -134 | N/A |
9/30/2019 | 55 | -166 | -127 | -123 | N/A |
6/30/2019 | 57 | -155 | -150 | -143 | N/A |
3/31/2019 | 65 | -167 | -164 | -152 | N/A |
12/31/2018 | 60 | -171 | -178 | -153 | N/A |
9/30/2018 | 197 | -21 | -49 | -14 | N/A |
6/30/2018 | 178 | -34 | -49 | -9 | N/A |
3/31/2018 | 160 | -32 | N/A | 18 | N/A |
12/31/2017 | 158 | -20 | N/A | 14 | N/A |
9/30/2017 | 10 | -160 | N/A | -126 | N/A |
6/30/2017 | 12 | -147 | N/A | -45 | N/A |
3/31/2017 | 91 | -66 | N/A | -47 | N/A |
12/31/2016 | 92 | -59 | N/A | -44 | N/A |
9/30/2016 | 95 | -52 | N/A | -40 | N/A |
6/30/2016 | 106 | -34 | N/A | -97 | N/A |
3/31/2016 | 32 | -96 | N/A | -89 | N/A |
12/31/2015 | 101 | -20 | N/A | -14 | N/A |
9/30/2015 | 98 | -11 | N/A | -10 | N/A |
6/30/2015 | 102 | 1 | N/A | -16 | N/A |
3/31/2015 | 104 | 10 | N/A | 5 | N/A |
12/31/2014 | 48 | -38 | N/A | -33 | N/A |
9/30/2014 | 57 | -20 | N/A | -14 | N/A |
6/30/2014 | 59 | -15 | N/A | 1 | N/A |
3/31/2014 | 62 | 0 | N/A | -4 | N/A |
12/31/2013 | 58 | 0 | N/A | -14 | N/A |
9/30/2013 | 53 | N/A | N/A | 5 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: MGNX devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: MGNX devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: MGNX devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de MGNX ( 12.2% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de MGNX ( 12.2% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: MGNX devrait être non rentable dans 3 ans.